Cardiome sees in New Year with glad tidings from Merck
This article was originally published in Scrip
Cardiome Pharma, the Canadian biotech company, says it has received seasonal cheer about its oral vernakalant mixed ion channel antagonist programme from its partner Merck & Co. The news that the US pharma had completed its review of the oral formulation of the atrial fibrillation (AF) compound and plans to move forward with clinical development in 2011 will be a relief to Cardiome's shareholders. Indeed, the company's share price advanced 9.2% to $6.55 on 30 December.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.